ライフサイエンスコーパス: BNP

1 BNP also stimulated the proliferation of WT1(+) epicardi

2 BNP and NT-proBNP were measured before and after 4 to 6

3 BNP and NT-proBNP were measured simultaneously at screen

4 BNP concentrations doubled in 141 (18%) patients and tri

5 BNP levels in the highest tertile were also associated a

6 BNP ratio (measured BNP/maximal normal BNP value specifi

7 BNP treatment increased their proliferation but not thei

8 BNP treatment increased vascularisation and the number o

9 BNP, NT-proBNP, hs-cTnT and hs-cTnI concentrations were

10 BNP, NT-proBNP, hs-cTnT, and hs-cTnI concentrations prov

11 BNP, NT-proBNP, hs-cTnT, and hs-cTnI cut-offs, achieving

12 BNP, NT-proBNP, hs-cTnT, and hs-cTnI were significantly

13 BNPs are readily suspended in water, facilitate adherenc

14 BNPs exhibited the greatest toxic potency to these two t

15 BNPs loaded with a potent chemotherapeutic agent [epothi

16 BNPs were also tested for hemolytic activity against she

17 er initial surgical treatment (n = 561, 42%) BNP activation did not impose excess long-term mortality

18 Three stages were developed based on a BNP higher than 81 pg/mL and a TnI higher than 0.1 ng/mL

19 In the derivation cohort, we found that a BNP threshold of more than 81 pg/mL best associated with

20 Achievement of absolute BNP thresholds reduced postdischarge all-cause mortality

21 1.15 to 1.54]; p < 0.0001), whereas absolute BNP was not (p = 0.43).

22 vival determinants, BNP clinical activation (BNP ratio >1) independently predicted mortality after di

23 with blood pressure, whereas those affecting BNP did not, highlighting the blood pressure-lowering ef

24 interval, 1.81-3.78; P for trend <0.001) and BNP (aHR, 1.45; 95% confidence interval, 1.03-2.04; P fo

25 aseline in levels of NT-proBNP (P=0.017) and BNP (P=0.002); these differences persisted after adjustm

26 f NT-proBNP was 2067 (Q1, Q3: 1217-4003) and BNP 318 (Q1, Q3: 207-559), and the ratio, calculated fro

27 tegories of hsTnI (aHR range, 0.50-0.60) and BNP (aHR range, 0.42-0.67) with no statistically signifi

28 ity cardiac troponin I (hsTnI) in 12 956 and BNP in 11 076 participants without cardiovascular diseas

29 eased cGMP production in response to ANP and BNP (all P<10(-6)), while cells expressing 541S NPR-A pr

30 hat the cardiac natriuretic peptides ANP and BNP and the guanylate cyclase-linked natriuretic peptide

31 gene dosage-dependent drop in atrial ANP and BNP content occurred.

32 ntaining the adjacent genes encoding ANP and BNP harbored 4 independent cis variants with effects spe

33 NPR-A function, the cGMP response to ANP and BNP was measured in cells expressing wild-type NPR1 and

34 Additionally, ANP and BNP were found to be the natural ligands for cell membra

35 s, the cardiac natriuretic peptides (ANP and BNP) are produced by cardiomyocytes in the developing he

36 The proBNP1-108 processing enzyme corin and BNP-degrading enzyme dipeptidyl peptidase-4 were reduced

37 B-lines, E/e', and BNP significantly increased during exercise (P<0.001 for

38 ional class, medical therapy escalation, and BNP [brain natriuretic peptide]).

39 adjustments for traditional risk factors and BNP levels, elevated TMAO levels remained predictive of

40 population, baseline cardiac troponin I and BNP were associated with the risk of vascular events and

41 normal and elevated hs-cTnI (>26.2 ng/L) and BNP (>100 pg/mL) were also studied.

42 g ultrasound (28-scanning point method), and BNP (B-type natriuretic peptide) assessment during supin

43 ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide), encoded by the cluster

44 Age, sex, and BNP and TnI concentrations were similar between the 25 p

45 and creatine kinase-MB (CK-MB), and TnI and BNP by CART.

46 Combining hs-TnI and BNP improved to predict long-term outcome (p = 0.004).

47 ve EuroSCORE risk with postoperative TNT and BNP after surgery allows for improved prediction of 1-ye

48 Postoperative TNT and BNP are strong predictors of 1-year events after on-pump

49 ed the net reclassification index of TNT and BNP in addition to the EuroSCORE.

50 s to assess the independent value of TNT and BNP to predict 12-month outcome after cardiac surgery wi

51 ssification index of the addition of TNT and BNP to the EuroSCORE was 0.276 (95% confidence interval,

52 We evaluated postoperative TNT and BNP, the EuroSCORE, and postoperative complications as p

53 -guanosine monophosphate) on binding of ANP, BNP (atrial or brain natriuretic peptide).

54 r atrial nor brain natriuretic peptide (ANP, BNP) is amidated, the major membrane protein in atrial g

55 In this large series of patients with AS, BNP clinical activation was associated with excess long-

56 tration in ascitic fluid, serum, and ascites BNP.

57 1.21) and results did not differ by baseline BNP concentration.

58 Main Outcome and Measures: Baseline BNP; subsequent hospitalization for heart failure or dea

59 In AS, the link between BNP levels and clinical outcome is in dispute.

60 Both BNP (B-type natriuretic peptide) and NT-proBNP (N-termin

61 Increases in both BNP and NT-proBNP during 8 to 10 weeks of sacubitril/val

62 in the cardiovascular protection provided by BNP.

63 Achievement of percentage-change BNP thresholds reduced the composite outcome (5 of 6 stu

64 nsitivity was observed in lean mice, chronic BNP infusion improved blood glucose control and insulin

65 Although circulating BNP levels are higher in women, when compared to age-mat

66 Combining BNP or NT-proBNP levels and echocardiographic parameters

67 Combining BNP/NT-proBNP with hs-cTnT/hs-cTnI further improved diag

68 M to a proportional hazards model containing BNP and left ventricular ejection fraction.

69 Results At a cutoff BNP of 100 ng/L as a marker of CHF, the correctly traine

70 lization, for example, cardiovascular death: BNP hazard ratio, 1.41 (95% CI, 1.33-1.49) per 1 SD incr

71 NP value specific to age and sex) >1 defined BNP clinical activation.

72 er adjustment for all survival determinants, BNP clinical activation (BNP ratio >1) independently pre

73 normal, perhaps contributing to differential BNP metabolism in HF.

74 e of cardiac surveillance (echocardiography, BNP, or cardiac imaging) in the year following completio

75 Elevated BNP and hs-cTnI identify candidates for targeted risk re

76 c features of CHF as reasons for an elevated BNP prediction more frequently than the overfitted model

77 zomib-based therapy with a baseline elevated BNP level higher than 100 pg/mL or N-terminal proBNP lev

78 e apparent evolution of HFpEF where elevated BNP is prevalent, MF was similarly prevalent in those wi

79 ntations of the labeled data set to estimate BNP.

80 sualize how a radiograph with high estimated BNP would look without disease (a "healthy" radiograph).

81 was developed in conjunction with a flexible BNP sensor to create a quick diagnostic tool.

82 etic resonance including 4-dimensional flow, BNP (brain-type natriuretic peptide) measurement, functi

83 <=4.13x10(-5) for ANP and P<=4.24x10(-3) for BNP).

84 tivation and 2.10 [95% CI: 1.32 to 3.36] for BNP ratio of 1 to 2, 2.25 [95% CI: 1.31 to 3.87] for BNP

85 o of 2 to 3, 3.93 [95% CI: 2.40 to 6.43] for BNP ratio of >/=3).

86 adjusted HR: 2.35 [95% CI: 1.57 to 3.56] for BNP clinical activation and 2.10 [95% CI: 1.32 to 3.36]

87 tic accuracy (C-statistics of 63% to 67% for BNP and C-statistics of 64% to 70% for NT-proBNP) with n

88 P (area under the curve of 0.85 vs. 0.74 for BNP) and Kaplan-Meier curves (log rank: 17.5 vs. 9.95).

89 o of 1 to 2, 2.25 [95% CI: 1.31 to 3.87] for BNP ratio of 2 to 3, 3.93 [95% CI: 2.40 to 6.43] for BNP

90 e a possible shared allelic architecture for BNP with aldosterone-renin ratio, and motivate further s

91 ) ng/L for hs-cTnI and 39 (15, 94) pg/mL for BNP.

92 em contained mRNA for NPR1, the receptor for BNP.

93 blood pressure with conflicting results for BNP.

94 We identified new roles for BNP that hold potential for new therapeutic strategies t

95 he release of reporter oligonucleotides from BNPs.

96 n cohort of 249 consecutive patients who had BNP, NT-proBNP, and TnI drawn simultaneously to create t

97 Higher BNP activation was associated with higher mortality (p <

98 Higher BNP is associated with mortality and cardiovascular and

99 Higher mortality with higher BNP clinical activation, even in asymptomatic patients,

100 This study highlights BNP's vasoprotective propensity, bringing to light a pos

101 At 1:1-2:1 RProt:HMP, BNPs showed appreciable turbidity, a nanometric diameter

102 MF was associated with disease severity (ie, BNP) and outcomes.

103 crease; it remains unclear whether change in BNP concentrations is similar across all assays for its

104 ril/valsartan led to inconsistent changes in BNP, which varied across methods assessed.

105 The observed increase in BNP concentration was proportional to the number of effe

106 r could promote significant LA protection in BNPs.

107 justing for potential confounders, including BNP, PH was found to be associated with HF hospitalizati

108 and PASP and potential mediators, including BNP (B-type natriuretic peptide) and endothelin-1.

109 For baseline models including BNP, the addition of H/M did not significantly increase

110 HFpEF, ECV was associated with baseline log BNP (disease severity surrogate) in multivariable linear

111 explained 0.4% and 1.9% of variation in log BNP concentration, respectively.

112 combining MELD score exceeding 25 and pre-LT BNP concentration exceeding 155 pg/mL had a 27% ICU mort

113 Pre-LT BNP concentration, adjusted on model of end-stage liver

114 66-0.93), the optimal cutoff value of pre-LT BNP serum level to predict ICU mortality was 155 pg/mL w

115 In cirrhotic patients, pre-LT BNP serum level was an independent predictor of post-LT

116 Mean BNP (B-type natriuretic peptide) was elevated (5743 pg/m

117 Early geometric mean BNP concentrations were similar at 72 h but significantl

118 BNP ratio (measured BNP/maximal normal BNP value specific to age and sex) >1

119 Thus, the clinical validity of measuring BNP in sacubitril/valsartan-treated patients has been qu

120 Median BNP concentration (before treatment: 202 ng/l [Q1 to Q3:

121 m(2); mean gradient 36 +/- 19 mm Hg), median BNP level was 252 pg/ml (interquartile range: 98 to 592

122 g/ml (interquartile range: 98 to 592 pg/ml); BNP ratio 2.46 (interquartile range 1.03 to 5.66); eject

123 ts with HF hospitalization within 12 months, BNP >=100 pg/mL or NT-proBNP >=400 pg/mL).

124 In 1,331 patients with degenerative MR, BNP was prospectively measured at diagnosis and expresse

125 onal bacterial membrane-coated nanoparticle (BNP) composed of an immune activating PC7A/CpG polyplex

126 old (Au) and Ag-Au bimetallic nanoparticles (BNPs), synthesized by use of this "green" method, were e

127 ue formulation of bioadhesive nanoparticles (BNPs) can interact with mesothelial cells in the abdomin

128 del UV filter--in bioadhesive nanoparticles (BNPs) prevents epidermal cellular exposure to UV filters

129 is conducted using biobarcode nanoparticles (BNPs) and results in the release of reporter oligonucleo

130 bout the design of biopolymer nanoparticles (BNPs) for polyunsaturated fatty acid (PUFA) vehiculizati

131 In addition, neither BNPs nor free BAR exhibited hemolytic activity.

132 ved xenografts compared with free EB and non-BNPs loaded with EB.

133 BNP ratio (measured BNP/maximal normal BNP value specific to age and sex) >1 defined BNP clinic

134 , and lack of accounting for shifting normal BNP ranges with age and sex.

135 ight-year survival was 62 +/- 3% with normal BNP levels, 44 +/- 3% with BNP ratio of 1 to 2 (adjusted

136 hese effects, tadalafil treatment normalized BNP mRNA and prevented development of subjective signs o

137 Although no acute effect of brain NP (BNP) on insulin sensitivity was observed in lean mice, c

138 mmonly used thresholds were a brain-type NP (BNP) level of 250 pg/mL or less or an amino-terminal pro

139 ne the in vivo efficacy of BAR-modified NPs (BNPs) and to assess the toxicity of BNPs against human g

140 Obtaining BNPs involved the electrostatic deposition of high metho

141 The prognostic accuracy of BNP, NT-proBNP, hs-cTnI, and hs-cTnT for MACE was modera

142 ed the diagnostic and prognostic accuracy of BNP, NT-proBNP, hs-cTnT, and hs-cTnI concentrations, alo

143 (95% confidence interval, 1.47-3.15) and of BNP >790 ng/L was 2.44 (95% confidence interval, 1.65-3.

144 Assessment of BNP (B-type natriuretic peptide) has also been suggested

145 mprove our knowledge of the genetic basis of BNP variation in blacks, demonstrate a possible shared a

146 edian (interquartile range) concentration of BNP (B-type natriuretic peptide) was 124 (69-197) ng/L,

147 assessed the cardiovascular consequences of BNP deletion in genetically null (Nppb-/-) female rat li

148 by genotype, and cardiorenal consequences of BNP knock out remained minor.

149 The processing and degradation of BNP molecular forms were altered but complete in HF, whi

150 sed a rightward shift in the distribution of BNP when compared with NT-proBNP, but both peptides reta

151 This study assessed the effect of BNP activation on mortality in a large, multicenter coho

152 ether part of the cardioprotective effect of BNP in infarcted hearts related to improved neovasculari

153 Simultaneous elevations of BNP and hs-cTnI over clinical cutoffs were strongly asso

154 demonstrate that the N-terminal extension of BNP is essential to virus viability not only for directi

155 nificance of this region on the functions of BNP and virus viability.

156 rognostic values (p < 0.0001) independent of BNP and traditional risk factors.

157 ce of appropriate clinical interpretation of BNP levels in managing patients with AS.

158 A level of BNP <40 pg/mL and NT-proBNP <125 pg/mL allowed identifyi

159 Circulating levels of BNP may increase meaningfully early after initiation of

160 t only for directing nuclear localization of BNP but also for regulating viral mRNA transcription and

161 are involved in the nuclear localization of BNP, with the entire N-terminal extension required for t

162 A program of prospective measurement of BNP levels with Doppler echocardiographic AS assessment

163 s to determine the prognostic performance of BNP measurements before and during treatment with sacubi

164 the cardiovascular protective propensity of BNP in females is poorly understood.

165 ibrotic, and anti-hypertrophic properties of BNP are well established in male animal models.

166 outcome were higher with higher quartiles of BNP after adjustment and remained statistically signific

167 Quartiles of BNP and high-sensitivity cardiac troponin I (hs-cTnI) we

168 and upon recent findings that this region of BNP is required for nuclear localization of the protein.

169 aining mutations in the first 10 residues of BNP demonstrated few differences in nuclear localization

170 ailure to account for the normal shifting of BNP ranges with aging in men and women, not using hard e

171 te for the first time that the N terminus of BNP is involved in regulating viral mRNA transcription a

172 the metabolite panel was better than that of BNP (area under the curve of 0.85 vs. 0.74 for BNP) and

173 cytotoxicity of the maximum concentration of BNPs and free BAR used in in vitro and in vivo studies (

174 In vivo efficacy of BNPs was assessed using a murine model of periodontitis

175 ation in vivo, highlighting the potential of BNPs as a biocompatible platform for translatable oral b

176 ied NPs (BNPs) and to assess the toxicity of BNPs against human gingival epithelial cells.

177 Although the sunblock based on BNPs contained less than 5 wt% of the UV-filter concentr

178 R: 0.68; 95% CI: 0.52 to 0.89; p = 0.003) or BNP ratio of >2 (HR: 0.56; 95% CI: 0.47 to 0.66; p < 0.0

179 d consistent regardless of baseline hsTnI or BNP concentrations.

180 cts specific to either midregional proANP or BNP and a rare missense single nucleotide polymorphism i

181 ), BNP, aminoterminal proBNP (NT-proBNP), or BNP:NT-proBNP ratio.

182 Infarcted mice were treated with saline or BNP for 10 days.

183 Pd-BNP showing a wide range of functional group tolerance a

184 hthyl stabilized palladium nanoparticles (Pd-BNP) catalyzed single-step, stereoselective domino synth

185 The Pd-BNP catalyst showed a wide range of functional group tol

186 The Pd-BNP has been recycled up to 5 catalytic cycles without a

187 using palladium binaphthyl nanoparticles (Pd-BNPs) has been developed.

188 on between serum B-type natriuretic peptide (BNP) activation and survival after the diagnosis of aort

189 plasma levels of B-type natriuretic peptide (BNP) and cardiac troponin I are associated with adverse

190 lso includes the B-type natriuretic peptide (BNP) and the C-type natriuretic peptide.

191 of postoperative B-type natriuretic peptide (BNP) are scarce.

192 -c3 (NFATc3), and brain natriuretic peptide (BNP) compared to controls.

193 heart failure and brain natriuretic peptide (BNP) concentration at baseline.

194 iac troponin and B-type natriuretic peptide (BNP) concentrations are associated with adverse cardiova

195 tein (hsCRP) and B-type natriuretic peptide (BNP) concentrations at 72 h and 12 weeks, and troponin I

196 artan treatment, B-type natriuretic peptide (BNP) concentrations increase; it remains unclear whether

197 prilysin; hence, B-type natriuretic peptide (BNP) concentrations rise with neprilysin inhibition.

198 eptide (ANP) and B-type natriuretic peptide (BNP) in heart tissue may also contribute to DXR resistan

199 eptide (ANP) and B-type natriuretic peptide (BNP) in response to mechanical stretching, making them u

200 B-type natriuretic peptide (BNP) is a guanylyl cyclase A (GC-A) agonist.

201 ies suggest that B-type natriuretic peptide (BNP) is cardioprotective; however, in clinical studies,

202 ven elevated brain-type natriuretic peptide (BNP) level; 160 had HFpEF by documented clinical diagnos

203 CI 1.02-2.2), log brain natriuretic peptide (BNP) levels (HR 1.45; 95% CI 1.15-1.81) and C-reactive p

204 ncentrations and B-type natriuretic peptide (BNP) levels (r = 0.23; p < 0.001).

205 d increased serum brain natriuretic peptide (BNP) levels.

206 suggesting that B-type natriuretic peptide (BNP) may predict outcomes of mitral regurgitation (MR) a

207 eptors expressing brain natriuretic peptide (BNP) most of them contained mRNA for NPR1, the receptor

208 elevated pre-TIPS brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro

209 Serum B-type natriuretic peptide (BNP) plays an important role in the diagnosis of HF.

210 Brain natriuretic peptide (BNP) serum concentration has been shown to be a preopera

211 ging system using brain natriuretic peptide (BNP) that would correlate with the Mayo 2004 staging sys

212 Brain natriuretic peptide (BNP) treatment increases heart function and decreases he

213 roponin I (TnI), B-type natriuretic peptide (BNP), and creatine kinase-MB (CK-MB), and TnI and BNP by

214 omarker for CVD, B-type Natriuretic Peptide (BNP), and echocardiographic parameters of diastolic dysf

215 ating RBP4, TTR, B-type natriuretic peptide (BNP), and troponin I (TnI) concentrations and electrocar

216 eptide (ANP) and B-type natriuretic peptide (BNP), have central roles in sodium and blood pressure re

217 The utility of B-type Natriuretic Peptide (BNP), N-terminal proBNP (NT-proBNP), and high-sensitivit

218 NP) and brain or B-type natriuretic peptide (BNP), thereby demonstrating an endocrine function for th

219 eported that pro-B-type natriuretic peptide (BNP)-1-108 circulates and is processed to mature BNP1-32

220 ion fraction and b-type natriuretic peptide (BNP).

221 value similar to B-type natriuretic peptide (BNP).

222 d data set (with B-type natriuretic peptide [BNP] result as a marker of CHF) and unlabeled data set (

223 levels of ANP (atrial natriuretic peptide), BNP (brain-type natriuretic peptide), and cGMP, and decr

224 on <=40%, and elevated natriuretic peptides: BNP >=150 pg/mL or NT-proBNP >=600 pg/mL (for patients w

225 es of heart failure, such as elevated plasma BNP.

226 however, in clinical studies, higher plasma BNP concentrations have been associated with incident ca

227 sed in a model with clinical indicators plus BNP, cTnI, ST2, PAPP-A, and MPO (each p</=0.01) [correct

228 LT for cirrhosis and for whom a preoperative BNP serum dosage was available between January 2011 and

229 lsartan Versus Enalapril on Effect on NT-pro BNP in Patients Stabilized From an Acute Heart Failure E

230 rohormone of brain naturetic peptide (NT pro-BNP) were low and did not change with acute exercise or

231 sted between the median pre- and post-NT-Pro-BNP (-387.0 (IQR: -1373.0-109), p = 0.0495).

232 D with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed

233 c, cardiac catheterization, and serum NT-pro-BNP analysis in patients with severe CPMR awaiting mitra

234 st to evaluate the difference between NT-Pro-BNP before and after PH therapy produced evidence that a

235 addition, to examine if preoperative NT-Pro-BNP can predict the risk for postoperative CPC.

236 he primary outcome for this study was NT-Pro-BNP changes and its association with fluid therapy and C

237 the normal range, a two-fold rise in NT-pro-BNP concentration and to more than 400 ng/L, or clinical

238 NT-pro-BNP concentrations decreased significantly and similarly

239 NT-pro-BNP increased with increasing fluid volumes all days (P

240 NT-pro-BNP increases with iv-fluid volumes given to colorectal

241 l surgical patients, and the level of NT-Pro-BNP is associated with CPC.

242 l to or greater than 2.5 m/second, an NT-pro-BNP level equal to or greater than 160 pg/ml, or RHC-con

243 Preoperative NT-Pro-BNP predicted CPC [odds ratio (confidence interval): 1.5

244 NT-Pro-BNP was elevated in the S-group compared with the R-grou

245 minal pro-B-type natriuretic peptide (NT-pro-BNP) concentration less than 250 ng/L.

246 sessed changes in N-terminal pro-BNP (NT-pro-BNP) from baseline to 6 months.

247 rminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by

248 eptor II, pro-brain natriuretic peptide (pro-BNP), and cardiac troponin T showed significant linear t

249 We also assessed changes in N-terminal pro-BNP (NT-pro-BNP) from baseline to 6 months.

250 N-terminal pro-BNP (NT-proBNP), copeptin (CT-proAVP), and miRNA express

251 regional pro-ANP (MR-proANP), N-terminal pro-BNP (NT-proBNP), proBNP(1-108), or C-type natriuretic pe

252 ociated with midregional proANP (MR-proANP), BNP, aminoterminal proBNP (NT-proBNP), or BNP:NT-proBNP

253 Change in ANP, MR-proANP, BNP (using 5 assays), NT-proBNP (3 assays), proBNP(1-108

254 anced reclassification, neither H/M results, BNP levels, nor left ventricular ejection fraction inter

255 Serum BNP is more accurate than ascites analyses in the diagno

256 ith MELD score exceeding 25 and pre-LT serum BNP level less than 155 pg/mL survived, whereas patients

257 ites could be streamlined by obtaining serum BNP as an initial test and could forego the need for dia

258 cites from other causes of ascites was serum BNP.

259 In summary, BNPs were non-toxic within the evaluated concentration r

260 In total, 157 syn-BNP cyclic peptides inspired by 96 nonribosomal peptide

261 The cyclic syn-BNP studies presented here provide further evidence of i

262 synthetic-bioinformatic natural product (syn-BNP) approach, which relies on bioinformatic algorithms

263 synthetic-Bioinformatic Natural Product (syn-BNP) approach.

264 Increasingly refined syn-BNP-based explorations of biosynthetic gene clusters sho

265 The syn-BNP approach replaces transcription, translation, and in

266 Here we report on expanding the syn-BNP approach to the design and synthesis of cyclic pepti

267 t pathogens susceptible to many of these syn-BNP antibiotics, but they were also unable to develop re

268 While no syn-BNPs we tested inhibited the growth of bacteria or yeast

269 ynthetic-bioinformatic natural products (syn-BNPs).

270 Using this approach, we screened syn-BNPs inspired by nonribosomal peptide synthetases agains

271 Therefore, we hypothesized that BNP would be useful in the differential diagnosis of asc

272 Mediation analysis showed that BNP and endothelin-1 explained 56% and 40%, respectively

273 Endothelial cell lineage tracing showed that BNP directly stimulated the proliferation of resident en

274 The BNP/NT-proBNP criteria were not different for patients i

275 Defects in the BNP/GC-A/cGMP pathway may play a role in arteriopathies

276 Moreover, the BNP-based sunblock significantly reduced double-stranded

277 flicting evidence as to the functions of the BNP N-terminal extension; however, this has never been a

278 This BNP can capture cancer neoantigens following RT, enhance

279 This BNP facilitates in situ immune recognition of a radiated

280 The ratio of NT-proBNP to BNP in heart failure and reduced ejection fraction appea

281 cardiac biomarkers ranging from troponin to BNP, N-terminal proBNP, and others.

282 tio 1.17), and higher median log-transformed BNP (hazard ratio 2.26) were associated with worse longe

283 Median log-transformed BNP and LV-GLS were 4.04 (absolute brain natriuretic pep

284 ddition of LV-GLS and median log-transformed BNP to a clinical model (Society of Thoracic Surgeons sc

285 ariable-adjusted logarithmically transformed BNP controlling for relevant covariates and population s

286 However, NP of influenza B viruses (BNP) contains an evolutionarily conserved N-terminal 50-

287 2; 95% CI: 1.63 to 2.75), and 15 +/- 2% with BNP ratio of >/=3 (adjusted HR: 2.43; 95% CI: 1.94 to 3.

288 /- 3% with normal BNP levels, 44 +/- 3% with BNP ratio of 1 to 2 (adjusted HR: 1.49; 95% CI: 1.17 to

289 1.49; 95% CI: 1.17 to 1.90), 25 +/- 4% with BNP ratio of 2 to 3 (adjusted HR: 2.12; 95% CI: 1.63 to

290 d by a similarly high margin (p = 0.54) with BNP ratio of <2 (HR: 0.68; 95% CI: 0.52 to 0.89; p = 0.0

291 d ratios per 1 B-line increment), along with BNP and E/e' ratio.

292 nyltransferase 4 gene GALNT4 associated with BNP:NT-proBNP ratio but not with BNP or midregional proA

293 e MR, incurred similar excess mortality with BNP activation.

294 ciated with BNP:NT-proBNP ratio but not with BNP or midregional proANP, suggesting effects on the pos

295 (control condition; n=677) or screening with BNP testing (n=697).

296 Combining hs-TnI with BNP helped better risk stratification.

297 ic melanoma or neuroblastoma, treatment with BNP+RT results in activation of DCs and effector T cells

298 Treatment of Pg/Sg infected mice with BNPs reduced bone loss and IL-17 expression almost to th

299 TIGKs treated with BNPs or free BAR demonstrated >90% viability and no sign

300 rker of CHF) and unlabeled data set (without BNP result).